Anna Eshoo: “I think that QALY measures are discriminatory, period.”

I find it hypocritical when I hear time and time and time again that plans are often blocked by PBMs from offering the lowest-priced generic.

The PBM Accountability Act will finally shed a light on the opaque drug pricing system.

This is, as you said and have said many times, this is a devastating disease, and I don't think this can be treated as 17 months of a little additional hope.

I support the legislation we are considering today to permanently authorize the THC GME program and fund new training sites to increase resident physician spots.